Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Daisuke Hidaka, Masahiro Onozawa, Naohiro Miyashita, Masao Nakagawa, Daigo Hashimoto, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 3369.

https://doi.org/10.1182/blood-2019-122999

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Telomerase Inhibition Impairs Self-Renewal of ß-Catenin Activated Myeloproliferative Neoplasm Progenitors

Wenxue Ma, MD PhD, Cayla Mason, BS, Ping Chen, MD PhD, Qingfei Jiang, PhD, Nathan Delos Santos, BS, Elisa Lazzari, PhD, Sheldon Morris, MD MPH, Phoebe Mondala, BS, Jane Isquith, BS, MS, Fei Huang, PhD, Larissa Balaian, PhD, Catriona Jamieson, MD PhD

Blood (2017) 130 (Supplement 1): 2860.

https://doi.org/10.1182/blood.V130.Suppl_1.2860.2860

Published: 2017

Journal Articles

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Jiajing Qiu, Fei Huang, PhD, Ronald Hoffman, MD, Xiaoli Wang, PhD

Blood (2017) 130 (Supplement 1): 1654.

https://doi.org/10.1182/blood.V130.Suppl_1.1654.1654

Published: 2017

Journal Articles

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

Pierre Fenaux, MD PhD, Azra Raza, MD, Edo Vellenga, MD, Uwe Platzbecker, MD, Valeria Santini, MD, Irina Samarina, MD, Koen Van Eygen, MD, Maria Díez-Campelo, MD PhD, Mrinal M. Patnaik, MDMBBS, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Aleksandra Rizo, MD PhD, David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 4256.

https://doi.org/10.1182/blood.V130.Suppl_1.4256.4256

Published: 2017

Journal Articles

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Claudia Bruedigam, PhD, Brad Wackrow, Axia Song, Amy H Porter, Stanley Chun-Wei Lee, PhD, Andrew S. Moore, MBBS FRACP PhD, Omar Abdel-Wahab, MD, Steven W Lane, PhD

Blood (2016) 128 (22): 578.

https://doi.org/10.1182/blood.V128.22.578.578

Published: 2016

Journal Articles

Ruxolitinib Restores Normal Telomere Length in Patients with Myelofibrosis

Giovanni Caocci, MD, Marianna Greco, PhD, Giuseppe Delogu, Christian Secchi, Alessandra Perra, Ghiani Silvia, Federica Orru, Adriana Vacca, Francesco Galimi, Giorgio La Nasa, MD

Blood (2016) 128 (22): 3116.

https://doi.org/10.1182/blood.V128.22.3116.3116

Published: 2016

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Caroline R Cantilena, BA, Xin Zhao, MD PhD, Sachiko Kajigaya, PhD, Neil Dunavin, MD, Xin Tian, PhD, Stephen A. Strickland, MD, Bipin N. Savani, MD, Sanjay R. Mohan, MD, Katayoun Rezvani, MDPhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Minoo Battiwalla, MDMS, Sawa Ito, MD, Austin John Barrett, MDFRCP,FRCPath

Blood (2015) 126 (23): 1267.

https://doi.org/10.1182/blood.V126.23.1267.1267

Published: 2015

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis

Ayalew Tefferi, MD, Aref Al-Kali, MD, Kebede H. Begna, MD, Mrinal M Patnaik, MBBS, Terra L. Lasho, PhD, Xiaolin Wang, ScD, Ying Wan, PhD, Curtis A. Hanson, MD

Blood (2015) 126 (23): 55.

https://doi.org/10.1182/blood.V126.23.55.55

Published: 2015

Journal Articles

Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN)

Camelia Iancu-Rubin, PhD, Goar Mosoyan, Craig C Parker, Kevin Eng, PhD, Ronald Hoffman, MD

Blood (2014) 124 (21): 4582.

https://doi.org/10.1182/blood.V124.21.4582.4582

Published: 2014

Journal Articles

Telomerase-Mediated Repair of Induced DNA Breaks Leads to Increased Genomic Instability in Multiple Myeloma Cells: Possible Mechanism and Translational Significance

Jagannath Pal, PhD, Masood Shammas, PhD, Subodh Kumar, PhD, Maria Gkotzamanidou, MD PhD, Puru Nanjappa, MS, Leutz Buon, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 5170.

https://doi.org/10.1182/blood.V124.21.5170.5170

Published: 2014

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Gabriela M. Baerlocher, MD, Monika Haubitz, PhD, Oliver G. Ottmann, MD, Olatoyosi Odenike, MBBS, Alexander Roeth, MD, Michael A McDevitt, MD PhD, Ted Shih, Bart Burington, Dianne Morfeld, Neeru Batra, BS, David Snyder, MD, Elisabeth Oppliger Leibundgut, PharmD

Blood (2014) 124 (21): 408.

https://doi.org/10.1182/blood.V124.21.408.408

Published: 2014

Journal Articles

Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML)

Claudia Bruedigam, Frederik Otzen Bagger, MSc, Catherine Paine Kuhn, Therese Vu, Rebecca Austin, Florian H Heidel, MD, Lars Bullinger, MD, PhD, Geoff R Hill, Scott A. Armstrong, MD, PhD, David A. Williams, MD, Steven W Lane, MD, PhD

Blood (2013) 122 (21): 2887.

https://doi.org/10.1182/blood.V122.21.2887.2887

Published: 2013

Journal Articles

Telomerase Contributes To Repair Of DNA Breaks In Myeloma Cells By Incorporating “TTAGGG” Sequences Within Genome: Biological and Translational Significance

Jagannath Pal, PhD, Jie Ding, PhD, Subodh Kumar, PhD, Zachary Hunter, Teresa Calimeri, MD, Jianhong Lin, Maria Gkotzamanidou, MD, Giovanni Parmigiani, PhD, Steven Treon, Masood Shammas, PhD, Nikhil Munshi, MD

Blood (2013) 122 (21): 1249.

https://doi.org/10.1182/blood.V122.21.1249.1249

Published: 2013

Journal Articles

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Ayalew Tefferi, MD, Kebede Begna, MD, Rebecca R. Laborde, PhD, Mrinal M Patnaik, MBBS, Terra L Lasho, MT, (ASCP), Darci Zblewski, Christy Finke, BS, Lauren Schimek, Betsy R. LaPlant, Curtis A. Hanson, MD, Monic J. Stuart, MD, MPH, Animesh Pardanani, MBBS, PhD

Blood (2013) 122 (21): 662.

https://doi.org/10.1182/blood.V122.21.662.662

Published: 2013

NARROW

Imetelstat Sensitizes Hematopoietic Malignancy Cells to Genotoxic Agent Via Suppression of Telomerase Mediated DNA Repair Process

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Telomerase Inhibition Impairs Self-Renewal of ß-Catenin Activated Myeloproliferative Neoplasm Progenitors

Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Ruxolitinib Restores Normal Telomere Length in Patients with Myelofibrosis

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis

Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN)

Telomerase-Mediated Repair of Induced DNA Breaks Leads to Increased Genomic Instability in Multiple Myeloma Cells: Possible Mechanism and Translational Significance

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML)

Telomerase Contributes To Repair Of DNA Breaks In Myeloma Cells By Incorporating “TTAGGG” Sequences Within Genome: Biological and Translational Significance

Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only